Pacific Edge (NZE:PEB, ASX:PEB) said its product Cxbladder Triage has been included by the American Urological Association as the standard of care in an amendment to its clinical guideline for microhematuria patients, according to a Friday filing with the Australian and New Zealand bourses.
The guideline mentions the product as the only urine-based biomarker test that has "Grade A" evidence from a randomized controlled trial in support of this recommendation, the filing said.
Company shares rose 5% in recent Monday trade in New Zealand and jumped almost 22% in Australia.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。